Tentative US approval for Merck’s diabetes therapy
July 21, 2017
Source: pharmatimes
476
The US Food and Drug Administration has given a tentative green light to Merck & Co’s follow-on biologic basal insulin Lusduna Nexvue.
The decision means that the drug has met all required regulatory standards for follow-on biologics of clinical and nonclinical safety, efficacy and quality, but is subject to an automatic stay due to a lawsuit from Sanofi claiming that it infringes on patents for its diabetes therapy Lantus (insulin glargine).
As per the Hatch-Waxman Act, Sanofi’s lawsuit, which was filed in September 2016 alleging infringement of 10 patents, prevents a final approval from the FDA on Lusduna Nexvue for either 30 months or in the event a court finds in favour of Merck, whichever comes sooner.
“The tentative approval of Lusduna Nexvue is an important milestone, bringing us closer to offering this medicine to patients,” noted Sam Engel, associate vp, Merck clinical research, diabetes, endocrinology, and women’s health.
Lusduna won clearance from the European Commission on January 4 as a biosimilar of Lantus, and can be used in patients aged at least two years for the treatment of diabetes.
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Disposable Medical Products that Keep Your Medical Facility Clean and Sterile March 31, 2022
- Bayer’s Kerendia approved in the US to slow CKD in type 2 diabetes patients August 26, 2021
- 10 Triumphant Drug Launches Of The Decade August 26, 2021
- Autoantibody order, timing predict genetically at-risk children most likely to get type 1 diabetes October 30, 2020
- Drugdu.com’s 4 most Popular Veterinary APIs and Veterinary medicine Suppliers September 6, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
